SCHEMBL6035945

SCHEMBL6035945

CCCc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1c(F)cccc1CC(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.35
PPARD Q03181 6/20 0.35
PPARA Q07869 6/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 1/20 0.35
HCRTR1 O43613 2/20 0.34
HCRTR2 O43614 1/20 0.34
SLC6A9 P48067 1/20 0.34
NR3C1 P04150 1/20 0.34
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
CYP2C9 P11712 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
PPARG P37231 1/20 0.34
RXRG P48443 1/20 0.34
ESR2 Q92731 1/20 0.34
ROCK2 O75116 1/20 0.33
LIPE Q05469 2/20 0.33
HDAC4 P56524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035210 0.93 GCGR (0.36) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2
SCHEMBL6035417 0.92 SMN1; SMN2 (0.36) GCGRPPARDPPARASMN1; SMN2HPGD
SCHEMBL6034571 0.91 GCGR (0.35) GCGRPPARDPPARASMN1; SMN2HPGD
SCHEMBL6035540 0.90 PPARG (0.40) GCGRPPARDPPARASMN1; SMN2HPGD
SCHEMBL6035752 0.90 SMN1; SMN2 (0.41) PPARDPPARASMN1; SMN2HPGDNR3C1
SCHEMBL6035477 0.90 GCGR (0.35) GCGRPPARDPPARASMN1; SMN2HPGD
SCHEMBL6034630 0.89 GCGR (0.34) GCGRPPARDSMN1; SMN2HPGDHCRTR1
SCHEMBL6035923 0.89 SMN1; SMN2 (0.36) GCGRPPARDPPARASMN1; SMN2HPGD
SCHEMBL6035208 0.88 HCRTR1 (0.38) GCGRPPARDPPARASMN1; SMN2HCRTR1
SCHEMBL6035863 0.87 PPARD (0.41) PPARDPPARASMN1; SMN2PPARGLIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 GCGR 93/4885PPARD 2488/4885PPARA 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.